Cure8

Why This Matters

The work highlights molecular differences between PSC-UC and typical UC that could help explain higher colorectal cancer risk in PSC-UC and suggests candidate miRNA biomarkers (eg, miR-155) for further study.

Who Should Pay Attention

Researchers, clinicians treating PSC-UC, and translational scientists interested in miRNA biomarkers

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This research analyzed paired colon biopsies (ascending and sigmoid) from patients with PSC, PSC-UC, UC, and controls and tested functional effects of miR-181a/b in cell lines. The authors report distinct miRNA signatures and pathway activation (PI3K/AKT, STAT3, NF-κB) between UC and PSC-UC, plus elevated serum miR-155 in PSC-UC.

The paper presents laboratory (molecular and cell-culture) findings and exploratory serum-miRNA classification analyses, not clinical trial results.

Keep In Mind

This classification is based on the article abstract and full-text extraction; the results are preclinical and exploratory (cell-line experiments and small biomarker analyses) and do not establish clinical diagnostic or treatment recommendations.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationCells
PublisherMDPI AG
AuthorsAlicja Łaba, Joanna Abramczyk, Michał Lubkowski +5 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 7, 2026, 12:00 AM
Content availableJournal abstract

Funding disclosed by the source: National Science Centre, award 2020/39/O/NZ4/01732; award 2020/39/O/NZ4/01732

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →